Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Novo Nordisk lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S.

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--is now no longer listed as being in short supply in the U.S. and the FDA has told anyone distributing copies of the ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...

Hims CEO Andrew Dudum said the company will continue to offer personalized compounded versions of semaglutide on its platform. In an effort to make Wegovy more accessible to cash-paying patients ...

That partnership will see Hims & Hers offer Novo Nordisk’s weight-loss drug Wegovy ... announced that it would stop offering compounded semaglutide, the active ingredient used in Wegovy and ...